NEW YORK CITY (dpa-AFX) - Radiopharmaceutical company Perspective
Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration
agreement with Bristol Myers Squibb Co. (BMY) to evaluate the safety and
tolerability of Perspective's targeted alpha-particle therapy (212Pb)VMT01 in
combination with Bristol Myers Squibb's nivolumab in patients with
histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R)
imaging scans.

This combination study is an amendment to the Company's ongoing Phase1/2a study
of (212Pb)VMT01 in patients with metastatic melanoma. The study has completed
enrollment in the first cohort and has commenced dosing in the second cohort.

Under the terms of the collaboration, Perspective will sponsor and fund the
combination study and Bristol Myers Squibb will provide nivolumab for use in the
study.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX